Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score

PURPOSE: Follow-up questionnaires (FUQs) are routinely used in pharmacovigilance to gather further information on suspected adverse drug reactions (ADRs) and are frequently included within Risk Management Plans. However, despite their extensive use and regulatory relevance, their contribution to improving the quality and completeness of case reports has not previously been evaluated quantitatively. The objective of this study was to assess whether the recommendation to implement or discontinue a FUQ was associated with changes in the completeness of information in case reports. METHODS: The minutes from January 2018 to July 2025 from the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) were screened to identify recommendations regarding FUQ implementation or discontinuation. For active substance-ADR combinations associated with a FUQ recommendation, case reports and a standardised measure of report completeness were obtained from EudraVigilance and VigiBase, the WHO global database of adverse event reports for medicines and vaccines, respectively. Interrupted time series analyses were conducted to assess the effect of specific FUQs on the quality of case reporting. RESULTS: Across the 27 active substance-ADR combinations evaluated, the impact of FUQs on report completeness was heterogeneous. Only six combinations showed statistically significant trend changes, of which one demonstrated a small improvement in completeness after FUQ implementation and five showed declining trends following implementation (n = 1) or discontinuation (n = 4). CONCLUSIONS: The present findings do not support a consistent association between FUQ implementation and improved case completeness. Other factors, including ADR-related characteristics and heterogeneity in pharmacovigilance data collection practices, may be more important determinants of report quality. These findings provide the first quantitative evidence on FUQ effectiveness and support a more evidence-based approach to their evaluation within pharmacovigilance systems.

Authors

Institutions

Publication Details

Journal
Pharmacoepidemiology and Drug Safety
Published
2026-11-18
DOI
https://doi.org/10.1002/pds.70527
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score

María Gordillo‐Marañón, Cristina Fernández‐Fernández
Pharmacoepidemiology and Drug Safety
Pharmacovigilance and Adverse Drug Reactions
article

Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score

María Gordillo‐Marañón, Cristina Fernández‐Fernández
article en

Abstract

PURPOSE: Follow-up questionnaires (FUQs) are routinely used in pharmacovigilance to gather further information on suspected adverse drug reactions (ADRs) and are frequently included within Risk Management Plans. However, despite their extensive use and regulatory relevance, their contribution to improving the quality and completeness of case reports has not previously been evaluated quantitatively. The objective of this study was to assess whether the recommendation to implement or discontinue a FUQ was associated with changes in the completeness of information in case reports. METHODS: The minutes from January 2018 to July 2025 from the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) were screened to identify recommendations regarding FUQ implementation or discontinuation. For active substance-ADR combinations associated with a FUQ recommendation, case reports and a standardised measure of report completeness were obtained from EudraVigilance and VigiBase, the WHO global database of adverse event reports for medicines and vaccines, respectively. Interrupted time series analyses were conducted to assess the effect of specific FUQs on the quality of case reporting. RESULTS: Across the 27 active substance-ADR combinations evaluated, the impact of FUQs on report completeness was heterogeneous. Only six combinations showed statistically significant trend changes, of which one demonstrated a small improvement in completeness after FUQ implementation and five showed declining trends following implementation (n = 1) or discontinuation (n = 4). CONCLUSIONS: The present findings do not support a consistent association between FUQ implementation and improved case completeness. Other factors, including ADR-related characteristics and heterogeneity in pharmacovigilance data collection practices, may be more important determinants of report quality. These findings provide the first quantitative evidence on FUQ effectiveness and support a more evidence-based approach to their evaluation within pharmacovigilance systems.

Pharmacoepidemiology and Drug SafetyVol. 35(12)
Agencia Española de Medicamentos y Productos Sanitarios (ES)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon